CRTSF logo

Chr. Hansen Holding A/S (CRTSF) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

CRTSF, $ (piyasa değeri 0) fiyatla Basic Materials işi olan Chr. Hansen Holding A/S'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 48/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
48/100 AI Puanı

Chr. Hansen Holding A/S (CRTSF) Malzemeler ve Emtia Maruziyeti

CEOMauricio Graber
Çalışanlar3834
MerkezHorsholm, DK
Halka Arz Yılı2012

Chr. Hansen Holding A/S is a global bioscience company specializing in natural ingredient solutions for the food, health, and agricultural sectors. With a focus on cultures, enzymes, and probiotics, the company enhances the taste, nutrition, and shelf life of various products, maintaining a strong market presence in diverse industries.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Chr. Hansen Holding A/S presents a compelling investment case based on its strong market position in the bioscience industry and its focus on natural ingredient solutions. The company's consistent profitability, demonstrated by a 17.0% profit margin and a 54.2% gross margin, highlights its operational efficiency. A key value driver is the increasing demand for natural and sustainable ingredients in the food, health, and agricultural sectors. Growth catalysts include the company's strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture. Potential risks include fluctuations in raw material prices and increasing competition within the specialty chemicals sector. Chr. Hansen's low beta of 0.33 suggests relatively low volatility compared to the overall market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $10.44 billion, reflecting its significant presence in the bioscience industry.
  • P/E ratio of 42.76, indicating investor expectations for future earnings growth.
  • Profit margin of 17.0%, showcasing the company's ability to generate profits from its revenue.
  • Gross margin of 54.2%, reflecting efficient cost management in the production of its natural ingredient solutions.
  • Beta of 0.33, suggesting lower volatility compared to the broader market.

Rakipler & Benzerleri

Güçlü Yönler

  • Strong market position in bioscience industry.
  • Diverse product portfolio of natural ingredient solutions.
  • Global presence and distribution network.
  • Commitment to innovation and sustainability.

Zayıflıklar

  • Reliance on specific industries (food, health, agriculture).
  • Exposure to fluctuations in raw material prices.
  • Limited dividend yield compared to some competitors.
  • OTC market trading may present liquidity challenges.

Katalizörler

  • Ongoing: Increasing demand for natural and sustainable ingredients in the food and health industries.
  • Ongoing: Strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture.
  • Upcoming: Potential expansion into new geographic markets in Asia Pacific and Latin America.
  • Ongoing: Growth in the probiotics market driven by increasing consumer awareness of health benefits.
  • Upcoming: Development of new and innovative solutions for the food cultures and enzymes market.

Riskler

  • Potential: Fluctuations in raw material prices impacting profitability.
  • Potential: Increasing competition from other bioscience companies.
  • Potential: Regulatory changes affecting the food and health industries.
  • Potential: Economic downturns impacting consumer spending.
  • Ongoing: OTC market trading may present liquidity challenges.

Büyüme Fırsatları

  • Expansion in Sustainable Agriculture: Chr. Hansen's collaboration with UPL Ltd. to develop microbial-based bio solutions for sustainable agriculture presents a significant growth opportunity. The global market for bio pesticides is projected to reach $10 billion by 2027, driven by increasing demand for eco-friendly farming practices. This partnership allows Chr. Hansen to leverage its bioscience expertise to capture a share of this rapidly expanding market, offering farmers sustainable alternatives to traditional chemical pesticides.
  • Increasing Demand for Probiotics: The global probiotics market is expected to reach $91.09 billion by 2032, growing at a CAGR of 7.4% from 2023. Chr. Hansen is well-positioned to capitalize on this trend through its Health & Nutrition segment, which produces probiotic products for dietary supplements, infant formula, and animal feed. As consumer awareness of the health benefits of probiotics increases, Chr. Hansen can expand its market share by developing innovative probiotic solutions and strengthening its distribution channels.
  • Growth in the Food Cultures and Enzymes Market: The market for food cultures and enzymes is driven by the increasing demand for processed and packaged foods with enhanced taste, texture, and shelf life. Chr. Hansen's Food Cultures & Enzymes segment can leverage this trend by developing customized solutions for the dairy, beverage, and bakery industries. The company's expertise in fermentation and enzyme technology provides a competitive advantage in meeting the evolving needs of food manufacturers.
  • Geographic Expansion in Emerging Markets: Chr. Hansen has the opportunity to expand its presence in emerging markets, particularly in the Asia Pacific and Latin America regions. These markets are experiencing rapid economic growth and increasing demand for natural ingredient solutions in the food, health, and agricultural sectors. By establishing local partnerships and tailoring its product offerings to meet regional preferences, Chr. Hansen can tap into new revenue streams and diversify its geographic footprint.
  • Strategic Acquisitions and Partnerships: Chr. Hansen can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. By acquiring companies with complementary technologies or market access, Chr. Hansen can accelerate its growth and innovation efforts. Strategic partnerships with research institutions and industry players can also provide access to new technologies and market opportunities.

Fırsatlar

  • Expansion in sustainable agriculture and bio solutions.
  • Increasing demand for probiotics and natural ingredients.
  • Geographic expansion in emerging markets.
  • Strategic acquisitions and partnerships.

Tehditler

  • Increasing competition from other bioscience companies.
  • Regulatory changes affecting the food and health industries.
  • Economic downturns impacting consumer spending.
  • Potential disruptions in supply chains.

Rekabet Avantajları

  • Proprietary technology in fermentation and enzyme production.
  • Strong brand reputation for quality and innovation.
  • Extensive portfolio of natural ingredient solutions.
  • Global distribution network and customer relationships.

CRTSF Hakkında

Founded in 1843 and headquartered in Hørsholm, Denmark, Chr. Hansen Holding A/S has evolved into a leading bioscience company with a global footprint. The company develops and provides natural ingredient solutions to the food, nutritional, pharmaceutical, and agricultural industries. Chr. Hansen operates through two primary segments: Food Cultures & Enzymes, and Health & Nutrition. The Food Cultures & Enzymes segment focuses on producing and selling cultures, enzymes, and probiotic products that enhance the taste, flavor, texture, shelf life, nutritional value, and health benefits of food products, particularly in the dairy industry. The Health & Nutrition segment offers solutions for dietary supplements, over-the-counter pharmaceuticals, infant formula, animal feed, and plant protection. Chr. Hansen's commitment to innovation and sustainability is underscored by its strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. With a long history of pioneering bioscience, Chr. Hansen continues to expand its offerings and global reach, serving a diverse range of customers across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region.

Ne Yaparlar

  • Develops natural ingredient solutions for the food industry.
  • Produces cultures and enzymes for dairy products.
  • Offers probiotic products for dietary supplements.
  • Provides solutions for the pharmaceutical industry.
  • Develops products for animal feed and plant protection.
  • Collaborates on microbial-based bio solutions for agriculture.
  • Enhances the taste, texture, and shelf life of food products.

İş Modeli

  • Develops and manufactures natural ingredients.
  • Sells products directly to food, health, and agricultural companies.
  • Generates revenue through product sales and licensing agreements.
  • Invests in research and development to innovate new solutions.

Sektör Bağlamı

Chr. Hansen Holding A/S operates within the specialty chemicals industry, which is characterized by innovation, sustainability, and increasing demand for natural ingredients. The global market for specialty chemicals is driven by the food, health, and agricultural sectors, with a growing emphasis on bio-based solutions. Chr. Hansen competes with companies like ACHHY (Ajinomoto Co., Inc.), ASGLF (Associated British Foods plc), AWCMY (Archer-Daniels-Midland Company), BOLIF (Koninklijke DSM N.V.), and HMTLY (Hormel Foods Corporation), each vying for market share through unique product offerings and strategic partnerships. The industry is witnessing a shift towards sustainable practices and consumer preferences for healthier, natural products, positioning Chr. Hansen favorably due to its focus on bioscience and natural ingredient solutions.

Kilit Müşteriler

  • Food manufacturers in the dairy, beverage, and bakery industries.
  • Dietary supplement companies producing probiotic products.
  • Pharmaceutical companies developing over-the-counter medications.
  • Agricultural companies seeking sustainable plant protection solutions.
AI Güveni: 72% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Chr. Hansen Holding A/S (CRTSF) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

CRTSF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

CRTSF için Wall Street fiyat hedefi analizi.

MoonshotScore

48/100

Bu puan ne anlama geliyor?

MoonshotScore, CRTSF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Mauricio Graber

CEO

Mauricio Graber serves as the CEO of Chr. Hansen Holding A/S. His career spans various leadership roles in the food and beverage industry. Before joining Chr. Hansen, he held significant positions at Nestlé, including Regional Business Head for the Infant Nutrition division in Latin America and CEO of Nestlé Mexico. Graber brings extensive experience in strategy, operations, and market development to his role at Chr. Hansen.

Sicil: Under Mauricio Graber's leadership, Chr. Hansen has focused on strengthening its position as a leading bioscience company and expanding its presence in sustainable agriculture. He has overseen strategic collaborations, such as the partnership with UPL Ltd., to develop innovative bio solutions. Graber has also emphasized the importance of sustainability and innovation in driving long-term growth for the company.

CRTSF OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Chr. Hansen Holding A/S (CRTSF) may have limited reporting requirements or may not meet the listing standards of higher tiers like OTCQX or OTCQB. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, OTC Other stocks often have less stringent financial and regulatory oversight, which can result in higher risks for investors due to potential information asymmetry and reduced transparency.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for CRTSF on the OTC market may be limited, potentially resulting in wider bid-ask spreads and greater price volatility. Lower trading volumes can make it more difficult for investors to buy or sell shares without significantly impacting the stock price. Investors should carefully assess the trading volume and bid-ask spread before investing to understand the potential challenges associated with liquidity.
OTC Risk Faktörleri:
  • Limited financial disclosure and transparency.
  • Potential for lower liquidity and higher price volatility.
  • Increased risk of fraud or manipulation.
  • Lack of regulatory oversight compared to major exchanges.
  • Information asymmetry and difficulty in conducting due diligence.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and reporting history.
  • Assess the company's management team and corporate governance practices.
  • Review the company's business model and competitive landscape.
  • Analyze the company's risk factors and potential liabilities.
  • Evaluate the company's liquidity and trading volume on the OTC market.
  • Consult with a financial advisor to assess the suitability of the investment.
  • Confirm the company's legal and regulatory compliance.
Meşruiyet Sinyalleri:
  • Established history as a bioscience company since 1843.
  • Global presence and operations in multiple regions.
  • Strategic collaborations with reputable companies like UPL Ltd.
  • Focus on innovation and sustainability.
  • Experienced management team led by CEO Mauricio Graber.

CRTSF Basic Materials Hisse Senedi SSS

CRTSF için değerlendirilmesi gereken temel faktörler nelerdir?

Chr. Hansen Holding A/S (CRTSF) şu anda yapay zeka skoru 48/100, düşük puanı gösteriyor. Temel güçlü yan: Strong market position in bioscience industry.. İzlenmesi gereken birincil risk: Potential: Fluctuations in raw material prices impacting profitability.. Bu bir finansal tavsiye değildir.

CRTSF MoonshotScore'u nedir?

CRTSF şu anda MoonshotScore'da 48/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

CRTSF verileri ne sıklıkla güncellenir?

CRTSF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler CRTSF hakkında ne diyor?

CRTSF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

CRTSF'a yatırım yapmanın riskleri nelerdir?

CRTSF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Fluctuations in raw material prices impacting profitability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

CRTSF'ın P/E oranı nedir?

CRTSF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CRTSF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

CRTSF aşırı değerli mi, yoksa düşük değerli mi?

Chr. Hansen Holding A/S (CRTSF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

CRTSF'ın temettü verimi nedir?

Chr. Hansen Holding A/S (CRTSF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is based on available data and may be subject to change.
  • OTC market data may be limited or less reliable than exchange-listed data.
Veri Kaynakları

Popüler Hisseler